- Breast
- Lung
- Hematologic Oncology
- Gastrointestinal
- Genitourinary
- General Oncology
- Sarcoma
- Skin
- Head & Neck
- Event
Playback speed
10 seconds
Ph-like ALL Therapy Should Be Different From the Other B-ALL: Targeted Therapy Consequence w/ TKI Are JAK2 Added to the Relapse Regimen or IO Approach
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Dieter Hoelzer
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Dieter Hoelzer
19 views
December 30, 2019
Comments 0
Login to view comments.
Click here to Login
Hematologic Oncology